GCP
KZR

GSA Capital Partners’s Kezar Life Sciences KZR Stock Holding History

GSA Capital Partners’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-28,260
Closed -$255K – 1858
2024
Q1 		$255K Buy
28,260
+2,219
+9% +$20.2K 0.02% 1297
2023
Q4 		$247K Buy
+26,041
New +$229K 0.02% 1212
2023
Q2 		– Sell
-9,764
Closed -$306K – 1746
2023
Q1 		$306K Buy
+9,764
New +$565K 0.03% 1016
2022
Q4 		– Sell
-4,269
Closed -$368K – 1690
2022
Q3 		$368K Buy
4,269
+1,736
+69% +$169K 0.05% 797
2022
Q2 		$209K Buy
+2,533
New +$223K 0.03% 1051
2021
Q3 		– Sell
-8,892
Closed -$483K – 1617
2021
Q2 		$483K Sell
8,892
-361
-4% -$20.5K 0.05% 652
2021
Q1 		$551K Sell
9,253
-1,809
-16% -$106K 0.09% 299
2020
Q4 		$577K Buy
11,062
+4,780
+76% +$266K 0.09% 345
2020
Q3 		$304K Buy
+6,282
New +$300K 0.05% 719
2019
Q4 		– Sell
-4,237
Closed -$139K – 1594
2019
Q3 		$139K Buy
+4,237
New +$205K 0.02% 1238

Other funds holding KZR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

GSA Capital Partners's KZR Position: Q2 2024 in Review

GSA Capital Partners sold out of Kezar Life Sciences (KZR) in Q2 2024, closing a stake of 28,260 shares — an estimated $255K sold.

GSA Capital Partners first reported a position in KZR in Q3 2019 and held it in 10 quarters. The position peaked at $577K in Q4 2020. 81 funds tracked by Wall St. Rank hold KZR as of Q2 2024.

  • GSA Capital Partners reported no remaining Kezar Life Sciences position as of Q2 2024 after selling out during the quarter.
  • GSA Capital Partners sold 28,260 Kezar Life Sciences shares in Q2 2024, an estimated $255K.
  • GSA Capital Partners first reported a position in Kezar Life Sciences in Q3 2019 and held it in 10 quarters.
  • GSA Capital Partners's Kezar Life Sciences position peaked at $577K in Q4 2020.
  • 81 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2024.

Based on GSA Capital Partners's 13F filing for Q2 2024, filed 15 Aug 2024.